BioScrip Inc (NASDAQ:BIOS) issued its quarterly earnings data on Thursday. The company reported ($0.12) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.10) by ($0.02), Briefing.com reports. The company had revenue of $198.70 million for the quarter, compared to analyst estimates of $202.91 million. BioScrip’s revenue was down 11.5% compared to the same quarter last year. During the same period last year, the firm posted ($0.12) earnings per share.

Shares of BioScrip (NASDAQ BIOS) traded down $0.33 during midday trading on Friday, reaching $2.07. 2,047,793 shares of the company’s stock traded hands, compared to its average volume of 961,951. BioScrip has a 1 year low of $0.98 and a 1 year high of $3.39. The company has a quick ratio of 1.57, a current ratio of 1.85 and a debt-to-equity ratio of -7.49.

In other BioScrip news, Director Michael G. Bronfein sold 27,000 shares of the stock in a transaction that occurred on Friday, September 15th. The stock was sold at an average price of $2.69, for a total transaction of $72,630.00. Following the completion of the sale, the director now directly owns 129,669 shares of the company’s stock, valued at approximately $348,809.61. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Coliseum Capital Management, L sold 2,846,941 shares of the stock in a transaction that occurred on Thursday, September 7th. The stock was sold at an average price of $2.93, for a total value of $8,341,537.13. The disclosure for this sale can be found here. Insiders have sold a total of 3,760,419 shares of company stock valued at $11,144,519 over the last ninety days. 0.80% of the stock is owned by insiders.

Several equities analysts recently commented on BIOS shares. SunTrust Banks, Inc. reissued a “buy” rating and issued a $3.00 price objective on shares of BioScrip in a research note on Friday. Jefferies Group LLC reissued a “buy” rating and issued a $4.00 price objective (up previously from $3.00) on shares of BioScrip in a research note on Thursday, August 10th. BidaskClub downgraded shares of BioScrip from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, August 1st. ValuEngine raised shares of BioScrip from a “sell” rating to a “hold” rating in a research note on Thursday, July 13th. Finally, Zacks Investment Research downgraded shares of BioScrip from a “buy” rating to a “hold” rating in a research note on Monday, August 14th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $3.60.

ILLEGAL ACTIVITY WARNING: This piece of content was published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of US & international copyright & trademark laws. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/bioscrip-inc-bios-issues-quarterly-earnings-results-misses-estimates-by-0-02-eps/1678406.html.

BioScrip Company Profile

BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.

Earnings History for BioScrip (NASDAQ:BIOS)

Receive News & Ratings for BioScrip Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.